Tumor Treating Fields (TTFields) show efficacy in Triple-Negative breast cancer (TNBC) cells alone and in combination with PARP inhibitor Talazoparib

被引：0
|
作者：
Ghandali, Maryam
Srinivasan, Praveen
Xia, Yutong
Wong, Eric T.
Sobol, Robert W.
Zhou, Lanlan
Carneiro, Benedito A.
Graff, Stephanie L.
El-Deiry, Wafik S.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7591
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7591
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.
    Cotte, Alexia
    Beniey, Michele
    Haque, Takrima
    Bechir, Nelly
    Hubert, Audrey
    Diallo, Korotoum W.
    Tran-Thanh, Danh
    Hassan, Saima N.
    CANCER RESEARCH, 2021, 81 (13)
  • [2] Characterization of PARP inhibitor combination therapies in triple-negative breast cancer
    Fyle, Elicia
    Abdesselam, Djihane
    Frederick, Mallory
    Hassan, Saima N.
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Combination benefit between PARP inhibitor niraparib and angiogenesis inhibitors in PDX models of triple-negative breast cancer (TNBC).
    Zhou, Yinghui
    Wang, Sarah
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing Yu
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 32 - 33
  • [4] In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab-paclitaxel on triple-negative and luminal A breast cancer cells
    Topcul, Mehmet
    Cetin, Idil
    Turan, Suna Ozbas
    Ozar, Melek Ozlem Kolusayin
    ONCOLOGY REPORTS, 2018, 40 (01) : 527 - 535
  • [5] In vitro efficacy of dasatinib alone or in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer cell lines
    Sun, Yuliang
    Carlson, Jennifer
    Lin, Xiaoqian
    De, Pradip
    Williams, Casey
    Hausman, Sally
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2016, 76
  • [6] Efficacy of combining tumor treating fields (TTFields) with a PARP inhibitor in ovarian cell lines
    Mulvey, Brett
    Martinez-Conde, Antonia
    Efimov, Vera
    Dor-On, Eyal
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S158 - S158
  • [7] Tumor-treating fields and concurrent cisplatin: an in vitro demonstration of efficacy in triple-negative breast cancer
    Smothers, Austin R.
    Beasley, Mya E.
    Warren, Hunter S.
    Kegel, Olivia G.
    Edenfield, W. Jeffery
    O'Connel, John J.
    Booth, Brian W.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2025, 15 (01): : 322 - 330
  • [8] Treatment of pancreatic cancer cells with tumor treating fields (TTFields) and PARP inhibitors
    Ene, Hila
    Ben Meir, Kerem
    Martinez-Conde, Antonia
    Frechtel-Gerzi, Roni
    Gabay, Hila
    Gerasimova, Daria
    Engelman, Rotem
    Dor-On, Eyal
    Haber, Adi
    Giladi, Moshe
    Palti, Yoram
    CANCER RESEARCH, 2024, 84 (06)
  • [9] Discovery of a small molecule inhibitor for triple-negative breast cancer (TNBC)
    Saran, Uttara
    Chandrasekaran, Balaji
    Tyagi, Ashish
    Singh, Amandeep
    Ankem, Murali K.
    Sharma, Arun K.
    Damodaran, Chendil
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triplenegative breast cancer (TNBC): Translational investigation
    Bardia, Aditya
    Coates, James T.
    Spring, Laura
    Sun, Sheng
    Juric, Dejan
    Thimmiah, Nayana
    Niemierko, Andrzej
    Ryan, Phoebe
    Partridge, Ann
    Peppercorn, Jeffrey
    Parsons, Heather
    Wander, Seth
    Pierce, Kelsey
    Attaya, Victoria
    Fitzgerald, Donna
    Lormil, Brenda
    Shellock, Maria
    Nagayama, Aiko
    Bossuyt, Veerle
    Moy, Bev
    Tolaney, Sara
    Ellisen, Leif
    CANCER RESEARCH, 2022, 82 (12)
12345